In the pipeline
Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.
- X
Our pipeline at a glance
As of October 31, 2024
51
Compounds in development
40+
Disease areas being studied
Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.
In the pipeline
Filter
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
Brand Name / Compound
Research Area / Line of Therapy
Phase 1 P 1
Phase 2 P 2
Phase 3 P 3
{"categoryColor":"#595454","phase":[{"name":"1 - Phase I","value":"bms:phase/phase-1","desc":"1"},{"name":"2 - Phase II","value":"bms:phase/phase-2","desc":"2"},{"name":"3 - Phase III","value":"bms:phase/phase-3","desc":"3"}],"listings":[{"compoundname":"<p><b>EGFRxHER3 ADC<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Solid Tumors *<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b><a href='/content/dam/packageinserts/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''>KRAZATI<\/a><sup>®<\/sup> (adagrasib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L NSCLC PD-L1≥50%<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b><a href='/content/dam/packageinserts/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''>KRAZATI<\/a><sup>®<\/sup> (adagrasib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>1L NSCLC PD-L1<50%<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='_blank' aria-label=''><b>OPDIVO<\/b><\/a><sup>®<\/sup><br>\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Stage IB-IIIA Adjuvant NSCLC *<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='' aria-label=''><b>OPDIVO<\/b><\/a><sup>®<\/sup><br>\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Adjuvant Hepatocellular Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":"<p><a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' title='' class='' target='' aria-label=''><b>OPDIVO<\/b><\/a><sup>®<\/sup><br>\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Peri-adjuvant Muscle-Invasive Urothelial Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/bladder"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_opdualag.pdf' title='' class='' target='_blank' aria-label=''>Opdualag<\/a> <sup>TM<\/sup> (nivolumab and relatlimab-rmbw)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Adjuvant Melanoma<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/melanoma"},{"compoundname":"<p><b>iberdomide<\/b><br />\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦2L+ Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>iberdomide<\/b><br />\r\n<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Post-Autologous Stem Cell Transplant Maintenance Newly Diagnosed Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>mezigdomide<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦2L+ Multiple Myeloma Vd<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>mezigdomide<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2L+ Multiple Myeloma Kd<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='_blank' aria-label=''>REBLOZYL<\/a><\/b><sup>®<\/sup> <br>\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L Non-Transfusion Dependent Myelodysplastic Syndrome-Associated Anemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/myelodysplastic-syndromes"},{"compoundname":"<p><b><a href='http://packageinserts.bms.com/pi/pi_breyanzi.pdf' title='' class='' target='_blank' aria-label=''>BREYANZI<\/a><sup>®<\/sup> (lisocabtagene maraleucel)<\/b><br>\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Relapsed/Refractory Marginal Zone Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>golcadomide<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦High Risk 1L Large B-cell Lymphoma<\/p>\r\n<p> <\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>golcadomide<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Relapsed/Refractory Follicular Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='_blank' aria-label=''>REBLOZYL<\/a><\/b><sup>®<\/sup> <br>\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>1L Transfusion Dependent Myelofibrosis-Associated Anemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/myelofibrosis"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Sjögren's Syndrome<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Psoriatic Arthritis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_sotyktu.pdf' title='' class='' target='_blank' aria-label=''>SOTYKTU<\/a>®<sup> <\/sup>(deucravacitinib)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Discoid Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>cendakimab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦Eosinophilic Esophagitis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>cendakimab<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Eosinophilic Gastroenteritis #<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>BMS-986322 (TYK2 Inhibitor)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Moderate-to-Severe Psoriasis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>afimetoran<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>admilparant (LPA1 Antagonist)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦Idiopathic Pulmonary Fibrosis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>admilparant (LPA1 Antagonist)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Progressive Pulmonary Fibrosis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>IL2-CD25<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>AR LDD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Metastatic Castration-Resistant Prostate Cancer<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/prostate"},{"compoundname":"<p><b>FAAH/MGLL Dual Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Neurodegenerative Diseases<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>GPRC5D CAR T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2-4L Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>GPRC5D CAR T<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Relapsed/Refractory Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_camzyos.pdf' title='' class='' target='_blank' aria-label=''>CAMZYOS<\/a>® (mavacamten)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Non-Obstructive Hypertrophic Cardiomyopathy<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>MYK-224<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>Obstructive Hypertrophic Cardiomyopathy <\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>MYK-224<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Heart Failure with Preserved Ejection Fraction<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>CD33 NKE<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Acute Myeloid Leukemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/acute-myeloid-leukemia"},{"compoundname":"<p><b>Anti-CCR8<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>CK1α Degrader<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Hematologic Malignancies<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/hematologic-malignancies"},{"compoundname":"<p><b>Anti-MTBR Tau<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>✦Alzheimer's Disease<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>eIF2B Activator<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Alzheimer's Disease<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>JNK Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>PKCθ Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p><b>✦<\/b>Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>subcutaneous relatlimab + nivolumab + rHuPH20<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦1L Melanoma<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/melanoma"},{"compoundname":"<p><b>milvexian *<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Acute Coronary Syndrome<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>milvexian *<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Atrial Fibrillation<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>milvexian *<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Secondary Stroke Prevention<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Severe Refractory Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Autoimmune Diseases<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>Helios CELMoD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>obexelimab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦IgG4-Related Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>BCL6 LDD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":"<p><b>BMS-986454<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":"<p><b>BMS-986460<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Prostate Cancer<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/prostate"},{"compoundname":"<p><b>CD33-GSPT1 ADC<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Acute Myeloid Leukemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/acute-myeloid-leukemia"},{"compoundname":"<p><b>Dual Targeting BCMAxGPRC5D CAR T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Relapsed/Refractory Multiple Myeloma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":"<p><b>BMS-986465 (TYK2 Inhibitor)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Neuroinflammation Disorders<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>PRMT5 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_krazati.pdf' title='' class='' target='_blank' aria-label=''>KRAZATI<\/a><sup>®<\/sup> (adagrasib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>2L Colorectal Cancer<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/colorectal"},{"compoundname":"<p><b>CD19 NEX-T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Multiple Sclerosis<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>RYZ101<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦2L+ SSTR2+ Gastroenteropancreatic Neuroendocrine Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>SOS1 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>RYZ101<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Extensive Stage Small Cell Lung Cancer<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>KRAS<sup>G12D<\/sup> Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''>COBENFY<\/a><sup>TM<\/sup> (KarXT)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Adjunctive Schizophrenia<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_cobenfy.pdf' title='' class='' target='_blank' aria-label=''>COBENFY<\/a><sup>TM<\/sup> (KarXT)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-3","researcharea":"<p>Psychosis in Alzheimer's Disease<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>TRPC4/5 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Mood and Anxiety Disorders<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b><a href='https://packageinserts.bms.com/pi/pi_reblozyl.pdf' title='' class='' target='' aria-label=''>REBLOZYL<\/a><\/b>® <br>\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"<p>A-Thalassemia<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/a-thalessemia"},{"compoundname":"<p><b>BMS-986495<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Neurodegenerative Diseases<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":"<p><b>BMS-986463<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>HbF Activating CELMoD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Sickle Cell Disease<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/sickle-cell-disease"},{"compoundname":"<p><b>nivolumab+relatlimab HD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦1L NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>BMS-986484<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":"<p><b>RYZ801<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦Hepatocellular Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":"<p><b>Anti-Fucosyl GM1 + nivolumab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"<p>✦1L Extensive Stage Small Cell Lung Cancer<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>RYZ101<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>HR+/HER2- Unresectable Metastatic Breast Cancer<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/breast"},{"compoundname":"<p><b>EGFRxHER3 ADC<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"<p>✦1L NSCLC *<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":"<p><b>EGFRxHER3 ADC<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"<p>Metastatic NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"}],"therapeuticarea":[{"color":"#dbc5c5","name":"bms:therapeutiic-area/cardiovascular","value":"Cardiovascular"},{"color":"#fedcca","name":"bms:therapeutiic-area/hematology","list":[{"name":"bms:tumor/a-thalessemia","value":"A-Thalessemia"},{"name":"bms:tumor/acute-myeloid-leukemia","value":"Acute Myeloid Leukemia (AML)"},{"name":"bms:tumor/hematologic-malignancies","value":"Hematologic Malignancies"},{"name":"bms:tumor/lymphoma","value":"Lymphoma"},{"name":"bms:tumor/multiple-myeloma","value":"Multiple Myeloma (MM)"},{"name":"bms:tumor/myelodysplastic-syndromes","value":"Myelodysplastic Syndromes (MDS)"},{"name":"bms:tumor/myelofibrosis","value":"Myelofibrosis (MF)"},{"name":"bms:tumor/sickle-cell-disease","value":"Sickle Cell Disease"}],"value":"Hematology"},{"color":"#c5ffe6","name":"bms:therapeutiic-area/immunology","value":"Immunology"},{"color":"#d8ddd1","name":"bms:therapeutiic-area/neuroscience","value":"Neuroscience"},{"color":"#c0f2fb","name":"bms:therapeutiic-area/solid-tumors","list":[{"name":"bms:tumor/bladder","value":"Bladder"},{"name":"bms:tumor/breast","value":"Breast"},{"name":"bms:tumor/colorectal","value":"Colorectal"},{"name":"bms:tumor/hepatocellular-carcinoma","value":"Hepatocellular Carcinoma (HCC)"},{"name":"bms:tumor/lung","value":"Lung"},{"name":"bms:tumor/melanoma","value":"Melanoma"},{"name":"bms:tumor/prostate","value":"Prostate"},{"name":"bms:tumor/solid-tumors","value":"Solid Tumors"}],"value":"Solid Tumors"}],"subCategoryColor":"#A69F9F"}
Please click on product name to see the Full U.S. Prescribing Information for OPDIVO®, YERVOY®, POMALYST®, EMPLICITI®, IDHIFA®, ISTODAX®, ORENCIA®, NULOJIX®, ELIQUIS®, REVLIMID®, REBLOZYL®, ZEPOSIA® , CAMZYOS® , ONUREG® including Boxed WARNINGS for ELIQUIS®, REVLIMID®, POMALYST® and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions and IDHIFA® regarding differentiation syndrome and INREBIC® regarding encephalopathy including Wernicke's.
Development Partnership: AUGTYRO: Zai Lab; EGFRxHER3 ADC: SystImmune; KarXT: Zai Lab; KRAZATI: Zai Lab; milvexian: Johnson & Johnson; obexelimab: Zenas BioPharma; OPDIVO, YERVOY, OPDUALAG: Ono; PKCθ Inhibitor: Exscientia; REBLOZYL: Merck; rHuPH20: Halozyme
* Partner-run study
◊ Product is marketed as IMNOVID® in the EU
# Japan only
✦ NME Lead Indication
NSCLC = Non-Small Cell Lung Cancer
SCLC = Small Cell Lung Cancer
TCE = T-Cell Engager
ADC = Antibody Drug Conjugate
ESA = Erythropoiesis-Stimulating Agent
For information on approved uses, refer to approved product labeling. Phase I - clinical trials investigating safety of an investigational medicine in a small number of human subjects. Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study. Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.